Biogen Surpasses Earnings Expectations Thanks to Alzheimer’s Drug Leqembi

Biogen has delivered an impressive financial performance, exceeding Wall Street's projections for the fourth quarter, primarily driven by the strong sales of its Alzheimer’s treatment, Leqembi. The company reported quarterly sales that not only surpassed analyst forecasts but also indicated a significant resurgence in demand for its pharmaceutical offerings.

Continue reading